Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European VC investment race hots up:

This article was originally published in Clinica

Executive Summary

Denmark and Sweden lead Europe's early-stage venture capital market ranking, investing 0.09% and 0.08% of their GDP. They are followed by the UK (with 0.05%), which is in turn the highest investor in expansion and replacement stage VC, with a 0.18% ratio. Sweden and Spain follow, with 0.16% and 0.15%, respectively. The Science, Technology and Innovation panorama report for 2004, published last week by Eurostat (the Statistical Office of the European Communities), analyses seed/start-up VC data for 16 of the EU25 states, and expansion/replacement VC data for a further two states. The average VC investment for each of the stages in the EU15 was 0.02% and 0.09%, respectively. News of the high UK rankings was welcomed by medtech industry association ABHI, but tempered with an attack on the poor domestic market conditions - notably procurement and innovation policies - that hinder start-up growth.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT053608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel